Dr. Lara on the Role of Sunitinib for Renal Cell Carcinoma

Primo N. Lara, MD
Published: Wednesday, Aug 02, 2017



Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the role of sunitinib (Sutent) for patients with renal cell carcinoma (RCC).

Sunitinib was shown in the S-TRAC trial to modestly improve disease-free survival for patients with completely resected RCC, explains Lara. Sunitinib as an adjuvant therapy has considerable toxicities that need to be managed.

According to Lara, even though sunitinib did see an increase in disease-free survival it had no clear benefit in terms of overall survival.

SELECTED
LANGUAGE


Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the role of sunitinib (Sutent) for patients with renal cell carcinoma (RCC).

Sunitinib was shown in the S-TRAC trial to modestly improve disease-free survival for patients with completely resected RCC, explains Lara. Sunitinib as an adjuvant therapy has considerable toxicities that need to be managed.

According to Lara, even though sunitinib did see an increase in disease-free survival it had no clear benefit in terms of overall survival.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x